18,032 Pfizer Inc. $PFE Shares Bought by Bank Pictet & Cie Europe AG

Bank Pictet & Cie Europe AG increased its holdings in shares of Pfizer Inc. (NYSE:PFE) by 5.6% during the third quarter, HoldingsChannel.com reports. The fund owned 338,410 shares of the biopharmaceutical company’s stock after buying an additional 18,032 shares during the quarter. Bank Pictet & Cie Europe AG’s holdings in Pfizer were worth $9,651,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also bought and sold shares of PFE. Retirement Wealth Solutions LLC grew its stake in Pfizer by 144.6% in the 3rd quarter. Retirement Wealth Solutions LLC now owns 861 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 509 shares during the period. Evolution Wealth Management Inc. raised its stake in shares of Pfizer by 132.2% during the 1st quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 566 shares during the period. Keb Asset Management LLC bought a new stake in shares of Pfizer during the 2nd quarter worth $26,000. Field & Main Bank purchased a new position in shares of Pfizer in the 2nd quarter worth about $27,000. Finally, Global Trust Asset Management LLC boosted its holdings in shares of Pfizer by 126.7% in the 1st quarter. Global Trust Asset Management LLC now owns 1,163 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 650 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Analysts Set New Price Targets

PFE has been the subject of several research reports. Bank of America reduced their price target on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating for the company in a research report on Friday, July 10th. Guggenheim reaffirmed a “buy” rating on shares of Pfizer in a research report on Tuesday, October 13th. HSBC boosted their target price on shares of Pfizer from $28.00 to $30.00 and gave the company a “hold” rating in a research note on Thursday, September 10th. Wall Street Zen downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Saturday, October 10th. Finally, BMO Capital Markets decreased their price target on shares of Pfizer from $34.00 to $30.00 and set an “outperform” rating for the company in a research note on Monday, July 13th. Five investment analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $28.72.

Pfizer Stock Performance

Shares of PFE stock traded up $0.69 on Tuesday, hitting $30.12. 16,798,089 shares of the stock were exchanged, compared to its average volume of 39,972,082. The company has a current ratio of 1.27, a quick ratio of 0.96 and a debt-to-equity ratio of 0.71. The firm has a market capitalization of $171.70 billion, a PE ratio of 39.64, a P/E/G ratio of 2.01 and a beta of 0.32. Pfizer Inc. has a one year low of $23.62 and a one year high of $30.23. The firm’s 50 day moving average is $28.05 and its two-hundred day moving average is $26.57.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.68 by $0.09. Pfizer had a return on equity of 19.63% and a net margin of 6.80%. The business had revenue of $15.03 billion for the quarter, compared to analysts’ expectations of $14.40 billion. During the same period in the previous year, the business posted $0.78 EPS. The firm’s quarterly revenue was up 2.6% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Sell-side analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 7th. Stockholders of record on Friday, November 6th will be paid a $0.43 dividend. The ex-dividend date is Friday, November 6th. This represents a $1.72 annualized dividend and a dividend yield of 5.7%. Pfizer’s dividend payout ratio (DPR) is presently 226.32%.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer is being viewed as a potential value-and-income turnaround. Its forward P/E near 10, substantial dividend and recent price momentum are attracting investors rotating from technology and artificial-intelligence stocks into defensive healthcare companies. Pfizer’s Stock Is Finally Showing Signs of Life
• Positive Sentiment: The broader biotechnology and pharmaceutical sector has shown relative strength during recent market weakness. Pfizer’s stability, recurring drug demand and proximity to its annual high make it one of the large-cap healthcare names investors are watching for further upside. Tech Stocks Took a Hit—These 2 Pharma Stocks Are Near New Highs
• Positive Sentiment: Pfizer’s oncology strategy remains an important part of the turnaround narrative, with recent cancer approvals and a multibillion-dollar oncology alliance cited as evidence of pipeline and portfolio renewal. What Pfizer Bulls Got Right
• Neutral Sentiment: Analysts remain cautious: Wells Fargo and RBC Capital reiterated Hold ratings, indicating that Pfizer’s valuation and dividend are attractive but the turnaround still needs to demonstrate durable earnings growth. Pfizer Gets a Hold from Wells Fargo
• Negative Sentiment: Investors are questioning whether Pfizer’s dividend is adequately covered by cash flow. The dividend freeze and high payout burden could limit financial flexibility if revenue remains pressured. Pfizer’s Dividend Freeze Raises a Bigger Question About Its Cash Flow
• Negative Sentiment: Upcoming results will be closely scrutinized for vaccine demand, pricing pressure and performance outside oncology, leaving execution and earnings visibility as key risks. Pfizer’s Non-Oncology Performance in Q3

Pfizer Company Profile

Pfizer Inc is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research activities span areas including oncology, internal medicine, inflammation and immunology, hospital care, infectious diseases and rare diseases.

The company’s portfolio includes medicines such as Eliquis, Ibrance, Prevnar and Vyndaqel, as well as vaccines including Comirnaty, Abrysvo and Prevnar. Pfizer also develops treatments through internal research, licensing agreements and collaborations with other pharmaceutical and biotechnology companies.

Founded in Brooklyn, New York, in 1849 by Charles Pfizer and Charles Erhart, Pfizer has grown into an international healthcare company serving patients and healthcare providers in markets around the world.